Reply

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposingfactors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33:1692–6. 2. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994; 38:409–14. 3. Van Burik J-AH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. Medicine (Baltimore) 1998; 77:246–54. 4. Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press, 1993:279–329. 5. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781–803, 804–805. 6. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99–109. 7. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 1991; 27:369–76. 8. Samonis G, Maraki S, Hajiioannou I, Chatzinikolaou I, Bodey GP, Kontoyiannis DP. Effect of ketaconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by C. albicans. J Chemother 2001; 13: 66–9. 9. Sheehan DJ, Hitchock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12:40–79. 10. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KVI. Itraconazole– amphotericin B antagonism in Aspergillus fumigatus: an E-test–based strategy. Antimicrob Agents Chemother 2000; 44:2915–8. 11. Slaven JW, Anderson MJ, Sanglard D, et al. Induced expression of a novel ABC transporter gene ADR1 form Aspergillus fumigatus in response to itraconazole [abstract 447]. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:550. 12. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382–402. 13. Becker JM, Heary LK, Jiang W, Koltin Y. Reduced virulence of Candida albicans mutants in multidrug resistance. Infect Immun 1995; 63:4515–8.